Salt Lake City - October 27, 2023 - BioUtah, Utah’s trade association serving the state’s life sciences community, announced today Myles Greenberg, MD, MBA, CEO of Alucent Biomedical, as the new board chair, effective January 2024.
Dr. Greenberg, an experienced life sciences entrepreneur, venture investor, and board-certified emergency physician, succeeds Andrea Kendell, chief financial officer at bioMérieux. Ms. Kendell will remain a member of the executive committee as immediate past chair. Completing the executive committee is Mark Paul, executive director of the University of Utah’s Center for Medical Innovation, and past president of Stryker Neurovascular, who will serve as board vice-chair.
“We are exceedingly grateful to outgoing Board Chair, Andrea Kendell, who successfully guided the BioUtah organization through a growth period that has resulted in a stronger, more robust life sciences ecosystem in Utah,” said Kelvyn Cullimore, president and CEO of BioUtah. “We also applaud the contributions of Brad Brown, executive chairman of ATL Technology, who will be rolling off the executive committee after three years of service, including as board chair in 2022 and vice-chair in 2021.”
Mr. Brown will remain an active member of the board going forward.
“The board is excited to welcome Dr. Greenberg who has long given his time and talent to advancing our industry,” added Cullimore. “We’re confident he will help us boldly further our mission.”
In addition to these leadership changes, five new directors have been appointed to the board effective immediately.
Jared Bauer, MBA, CEO, Seek Labs
Mr. Bauer’s career has been concentrated in the medical technology industry with a focus on advancing healthcare innovation. In 2016, he co-founded Seek Labs, a diagnostics and pharmaceutical development company. In 2012, he acquired BurnFree Products, and led the team to expand BurnFree distribution to 58 countries before a successful exit in 2016. Mr. Bauer also serves as the chair of BioHive, an entity created by BioUtah and spun off to be a separate 501(c)3 in June of 2023.
David Bearss, PhD, CEO, Halia Therapeutics
Dr. Bearss is an experienced entrepreneur and drug developer with more than 20 years of experience in academic and industry settings. He has discovered 16 compounds that have moved forward in clinical development and has founded eight biotech companies. As the co-founder and CEO of Halia, Dr. Bearss is developing new therapies targeting chronic inflammation. Prior to joining Halia, Dr. Bearss was the CEO of Tolero Pharmaceuticals, which was acquired by Sumitomo Dianippon Pharma in 2017.
Haven McCall, PhD, CEO, Canyon Labs
As the founder and CEO of Canyon Labs since its creation in 2020, Dr. McCall oversees a team of experts who provide laboratory testing, quality, regulatory, scientific, and technical consulting for products ranging from medical devices to biologics. He is an experienced leader who has spent more than 23 years working at large multinational corporations in the areas of clinical research, quality, and regulatory.
Phil Prentice, MBA, VP, Global Platform Leader, BD
Mr. Prentice is an executive leader at BD, one of the largest medical technology companies in the world focused on advancing medical discovery, diagnostics and delivery of care. At BD, he leads the advanced vascular access device business. He has more than 20 years of experience building innovative product platforms, spanning a wide range of high-level roles across medical device, orthodontics, and dental industries. Prior to BD, Phil held executive leadership roles at Henry Schein, Danaher, and Johnson and Johnson. He replaces Kate Benedict, who has had a change in assignment with BD.
Josh Walker, MBA, COO, Nomi Health
A seasoned healthcare leader with over 20 years of experience, Mr. Walker’s expertise spans the U.S., Southeast Asia, India, the Middle East, and Europe. He has successfully managed complex operational and strategic healthcare initiatives. He is currently the co-founder and COO at Nomi Health. Previously, Walker served as the COO of Imagine Health. He has also held leadership roles at Red Pine Consulting, United Health Group, Optum, and Huntsman Biotechnology Corporation.
Four members of the board are departing:
- Kate Benedict, CPA, MBA, VP general manager, Strategic Innovation and Vascular Access Devices, BD
- Kolby Day, JD, COO, BiomeBank, formerly with PolarityTE
- Chris Gibson, PhD, Co-Founder and CEO, Recursion Pharmaceuticals
- Keith Marmer, DPT, MBA, president, Seek Labs and Managing Partner, UVB Capital, formerly with the University of Utah
BioUtah is governed by a board of 15 directors representing the breadth and depth of Utah’s life sciences industry.
For more information on the organization’s governance, visit BioUtah.org
